Arbutamine stress echocardiography

Eur Heart J. 1997 Jun;18 Suppl D:D24-30. doi: 10.1093/eurheartj/18.suppl_d.24.

Abstract

Arbutamine, a new potent non-selective beta-adrenoceptor agonist with mild alpha 1-sympathomimetic activity, has been developed specifically for pharmacological stress testing. The drug acts like physical exercise, increasing both heart rate and myocardial contractility. Sensitivity, specificity and accuracy in detecting significant stenotic coronary artery disease are 76%, 96%, and 82%, respectively, again similar to those of exercise echocardiography. The drug is delivered by a computerized drug delivery and monitoring device (GenESA) which adjusts the infusion rate according to the patient's heart rate data feedback. The drug is generally well tolerated and has an acceptable safety profile. This article describes recent clinical experience with arbutamine and presents preliminary results of a multicentre multinational study which evaluates the clinical utility and safety of the GenESA system in diagnosing coronary artery disease.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Agonists* / administration & dosage
  • Animals
  • Catecholamines* / administration & dosage
  • Clinical Trials as Topic
  • Coronary Disease / diagnosis*
  • Drug Delivery Systems / instrumentation
  • Drug Therapy, Computer-Assisted / instrumentation
  • Echocardiography / methods*
  • Exercise Test / methods*
  • Hemodynamics / drug effects
  • Hemodynamics / physiology
  • Humans
  • Sensitivity and Specificity

Substances

  • Adrenergic beta-Agonists
  • Catecholamines
  • arbutamine